muscle pain; muscle ache; swollen lymph nodes; fever chills; headache; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory authority (ra). regulatory number: gb-mhra-webcovid-202202170547079860-m7l27. other case identifier(s): gb-mhra-adr 26612291. a 25-year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 16feb2022 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "covid-19", start date: 13dec2021 (unspecified if ongoing). the patient's concomitant medications were not reported. vaccination history included: bnt162b2 (dose 1), for covid-19 immunization, reaction(s): "covid-19 positive"; bnt162b2 (dose 2), for covid-19 immunization, reaction(s): "covid-19 positive". the following information was reported: myalgia (medically significant), outcome "not recovered", described as "muscle pain"; myalgia (medically significant), outcome "not recovered", described as "muscle ache"; lymphadenopathy (medically significant), outcome "not recovered", described as "swollen lymph nodes"; pyrexia (medically significant), outcome "not recovered", described as "fever chills"; headache (medically significant), outcome "not recovered", described as "headache". the patient underwent laboratory test: covid-19 virus test: (13dec2021) positive, notes: yes - positive covid-19 test. clinical course: patient has not had symptoms associated with covid-19. patient was not currently breastfeeding. patient was not enrolled in clinical trial. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test date: 20211213; test name: covid-19 virus test; test result: positive ; comments: yes - positive covid-19 test

na

na